JP2022504036A5 - - Google Patents
Info
- Publication number
- JP2022504036A5 JP2022504036A5 JP2021517954A JP2021517954A JP2022504036A5 JP 2022504036 A5 JP2022504036 A5 JP 2022504036A5 JP 2021517954 A JP2021517954 A JP 2021517954A JP 2021517954 A JP2021517954 A JP 2021517954A JP 2022504036 A5 JP2022504036 A5 JP 2022504036A5
- Authority
- JP
- Japan
- Prior art keywords
- reuptake inhibitors
- agent
- antidepressant
- serotonin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024078458A JP2024105527A (ja) | 2018-10-05 | 2024-05-14 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741562P | 2018-10-05 | 2018-10-05 | |
| US62/741,562 | 2018-10-05 | ||
| IBPCT/IB2018/059107 | 2018-11-19 | ||
| PCT/IB2018/059107 WO2020070547A1 (en) | 2018-10-05 | 2018-11-19 | Dosage regime of esketamine for treating major depressive disorder |
| US201962867354P | 2019-06-27 | 2019-06-27 | |
| US62/867,354 | 2019-06-27 | ||
| PCT/IB2019/058476 WO2020070706A1 (en) | 2018-10-05 | 2019-10-04 | Dosage regime of esketamine for treating major depressive disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078458A Division JP2024105527A (ja) | 2018-10-05 | 2024-05-14 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022504036A JP2022504036A (ja) | 2022-01-13 |
| JP2022504036A5 true JP2022504036A5 (https=) | 2023-11-10 |
Family
ID=70551470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517954A Pending JP2022504036A (ja) | 2018-10-05 | 2019-10-04 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
| JP2024078458A Pending JP2024105527A (ja) | 2018-10-05 | 2024-05-14 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078458A Pending JP2024105527A (ja) | 2018-10-05 | 2024-05-14 | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US11865088B2 (https=) |
| EP (1) | EP3860579A1 (https=) |
| JP (2) | JP2022504036A (https=) |
| KR (1) | KR20210074275A (https=) |
| CN (1) | CN112702995A (https=) |
| AU (1) | AU2019352028A1 (https=) |
| CA (1) | CA3113198A1 (https=) |
| IL (1) | IL280845A (https=) |
| WO (1) | WO2020070706A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| BR112020023882A2 (pt) | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US12589083B2 (en) | 2019-05-07 | 2026-03-31 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| EP3949956A1 (en) * | 2020-08-06 | 2022-02-09 | LTS Lohmann Therapie-Systeme AG | Esketamine-suspension-tts |
| WO2022248621A1 (en) | 2021-05-25 | 2022-12-01 | Awakn Ls Europe Holdings Limited | Ketamine the treatment of behavioural addictions |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| US7399488B2 (en) | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| AU2008286914B2 (en) | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| JP2011520815A (ja) | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| BR112015000150A2 (pt) | 2012-07-06 | 2017-06-27 | Egalet Ltd | composições farmacêuticas dissuasoras de abuso de liberação controlada |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| US9468611B2 (en) | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| DK2983787T3 (da) * | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| CA2922507C (en) | 2013-08-26 | 2022-07-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| WO2015051259A1 (en) | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
| EA032013B1 (ru) | 2013-10-31 | 2019-03-29 | Сайма Лэбс Инк. | Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением |
| PL3287124T3 (pl) | 2014-04-17 | 2023-02-20 | Ketabon Gmbh | Doustna postać dawkowania ketaminy |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| DK3215147T3 (da) | 2014-11-04 | 2024-04-02 | Acadia Pharm Inc | Neurodæmpende norketamin-forbindelser og fremgangsmåder |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| WO2017041112A1 (en) * | 2015-09-04 | 2017-03-09 | Cyprus Therapeutics, Inc. | Ketamine and cytochrome p 450 inhibitor combinations |
| US11110070B2 (en) | 2015-11-17 | 2021-09-07 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| AU2017351437B2 (en) * | 2016-10-27 | 2022-01-27 | National University Corporation Chiba University | Application of (S)-norketamine and salt thereof as pharmaceutical |
| ES2991544T3 (es) | 2016-11-30 | 2024-12-04 | Wolfson Philip E | Ketamina para el tratamiento de síntomas relacionados con la menstruación |
| WO2018234568A2 (en) * | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION |
| CN111630026A (zh) | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
| KR20240011237A (ko) | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| BR112020023882A2 (pt) | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| CN112702995A (zh) * | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| CA3133012A1 (en) | 2019-08-05 | 2021-02-11 | The Ketamine Research Foundation | Ketamine for the treatment of postpartum symptoms and disorders |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
-
2019
- 2019-10-04 CN CN201980058745.4A patent/CN112702995A/zh active Pending
- 2019-10-04 JP JP2021517954A patent/JP2022504036A/ja active Pending
- 2019-10-04 US US16/592,930 patent/US11865088B2/en active Active
- 2019-10-04 CA CA3113198A patent/CA3113198A1/en active Pending
- 2019-10-04 AU AU2019352028A patent/AU2019352028A1/en not_active Abandoned
- 2019-10-04 KR KR1020217006938A patent/KR20210074275A/ko not_active Ceased
- 2019-10-04 EP EP19782762.9A patent/EP3860579A1/en not_active Withdrawn
- 2019-10-04 WO PCT/IB2019/058476 patent/WO2020070706A1/en not_active Ceased
-
2021
- 2021-02-14 IL IL280845A patent/IL280845A/en unknown
- 2021-04-13 US US17/229,623 patent/US11253487B2/en active Active
-
2022
- 2022-01-10 US US17/571,731 patent/US12016832B2/en active Active
-
2023
- 2023-03-30 US US18/193,122 patent/US11957645B2/en active Active
- 2023-11-08 US US18/504,388 patent/US12280022B2/en active Active
- 2023-11-14 US US18/508,826 patent/US12514831B2/en active Active
- 2023-11-22 US US18/517,062 patent/US12336970B2/en active Active
-
2024
- 2024-05-14 JP JP2024078458A patent/JP2024105527A/ja active Pending
-
2025
- 2025-03-06 US US19/072,349 patent/US20250195454A1/en active Pending
- 2025-05-21 US US19/214,604 patent/US20250281428A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022504036A5 (https=) | ||
| US11786491B2 (en) | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders | |
| JP2015535290A5 (https=) | ||
| JP2015516395A5 (https=) | ||
| JP2011523949A5 (https=) | ||
| JP2021519271A5 (https=) | ||
| JP5827239B2 (ja) | フマギロール型化合物並びにその製造方法及び使用方法 | |
| RU2016143091A (ru) | Органические соединения | |
| JP2023100904A5 (https=) | ||
| JP6479670B2 (ja) | ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法 | |
| HRP20110206T1 (hr) | Derivati 3-(heteroaril-oksi)-2-alkil-1-aza-bicikloalkila kao alfa.7-nachr liganda za liječenje cns bolesti | |
| JP2017509686A5 (https=) | ||
| RU2020123764A (ru) | Органические соединения | |
| RU2018137496A (ru) | Органические соединения | |
| JP2021511365A5 (https=) | ||
| JP2002520273A5 (https=) | ||
| MXPA06002619A (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion. | |
| JP2022506113A5 (https=) | ||
| JP2009500421A (ja) | エスゾピクロン及び抗うつ薬の組み合わせ | |
| JP2013032308A5 (https=) | ||
| JP2016520112A5 (https=) | ||
| TWI455712B (zh) | 增強神經藥方療效的山梨酸與苯甲酸及其衍生物 | |
| JP2009542820A5 (https=) | ||
| WO2012083034A1 (en) | Modulation of neurotrophic factors by omega-3 fatty acid formulations | |
| JP2024538015A5 (https=) |